Get the Stockscreener App
26.88
8.85%
-2.61
After Hours:
27.30
0.42
+1.56%
Sensei Biotherapeutics Inc stock is traded at $26.88, with a volume of 76,216.
It is down -8.85% in the last 24 hours and down -11.05% over the past month.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
See More
Previous Close:
$29.49
Open:
$28.97
24h Volume:
76,216
Relative Volume:
0.26
Market Cap:
$33.91M
Revenue:
-
Net Income/Loss:
$-26.82M
P/E Ratio:
-2.5237
EPS:
-10.6509
Net Cash Flow:
$-24.28M
1W Performance:
-12.01%
1M Performance:
-11.05%
6M Performance:
+205.45%
1Y Performance:
+208.26%
1-Day Range:
$26.58
$30.68
1-Week Range:
$26.58
$35.00
52-Week Range:
$5.00
$36.76
Sensei Biotherapeutics Inc Stock (SNSE) Company Profile
Name
Sensei Biotherapeutics Inc
Sector
Industry
Phone
(240) 243-8000
Address
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare SNSE vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNSE
Sensei Biotherapeutics Inc
|
26.88 | 37.21M | 0 | -26.82M | -24.28M | -10.65 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Sensei Biotherapeutics Inc Stock (SNSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| May-14-24 | Initiated | Stephens | Overweight |
| Jul-01-21 | Downgrade | Berenberg | Buy → Hold |
| Jun-29-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-01-21 | Initiated | Berenberg | Buy |
| Mar-01-21 | Initiated | Citigroup | Buy |
| Mar-01-21 | Initiated | Oppenheimer | Outperform |
| Mar-01-21 | Initiated | Piper Sandler | Overweight |
View All
Sensei Biotherapeutics Inc Stock (SNSE) Latest News
Aug Chart Watch: What is Sensei Biotherapeutics Incs TAM Total Addressable Market2026 WrapUp & Real-Time Market Trend Scan - baoquankhu1.vn
If You Invested $1,000 in Sensei Biotherapeutics, Inc. (SNSE) - Stock Titan
Decliners Report: Does Sensei Biotherapeutics Inc have pricing power2026 Sector Review & Long-Term Safe Investment Plans - baoquankhu1.vn
Aug Technicals: What is the Moat Score of Sensei Biotherapeutics Inc2026 PreEarnings & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Momentum Shift: Can Sensei Biotherapeutics Inc be the next market leaderWeekly Profit Recap & Capital Efficient Trade Techniques - baoquankhu1.vn
SNSE.O PE Ratio & Valuation, Is SNSE.O Overvalued - Intellectia AI
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology - GlobeNewswire Inc.
Anand Kiran Parikh Net Worth (2026) - GuruFocus
Sensei Biotherapeutics announces inducement grants under Nasdaq listing rule - TipRanks
Sensei Biotherapeutics (SNSE) Announces Stock Option Grant to Ne - GuruFocus
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PharmiWeb.com
Sensei Biotherapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Why Sensei Biotherapeutics Inc. stock is favored by pension funds2026 Pullbacks & Reliable Entry Point Trade Alerts - Naître et grandir
Update Recap: How buybacks impact Sensei Biotherapeutics Inc. stock valueCEO Change & Comprehensive Market Scan Insights - Naître et grandir
Published on: 2026-03-07 01:25:22 - Naître et grandir
Can Sensei Biotherapeutics Inc be the next market leaderQuarterly Profit Review & Technical Confirmation Alerts - baoquankhu1.vn
Rate Hike: Is Sensei Biotherapeutics Inc a strong growth stockMarket Activity Recap & Stepwise Trade Execution Plans - baoquankhu1.vn
Fed Meeting: Whats next for CRWD stock2025 Market WrapUp & Accurate Entry/Exit Alerts - baoquankhu1.vn
Trails Edge Capital Partners, LP Acquires Shares in Sensei Bioth - GuruFocus
Revenue Check: Is Sensei Biotherapeutics Inc being accumulated by smart moneyWeekly Gains Summary & Accurate Buy Signal Notifications - baoquankhu1.vn
Sensei Biotherapeutics grants stock options to 17 new employees - Investing.com
Trails Edge files 9.9% ownership in Sensei Biotherapeutics (NASDAQ: SNSE) - Stock Titan
SNSE (NASDAQ: SNSE) insider schedules sale of 3,374 shares; prior sale 42,594 - Stock Titan
SNSE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Sensei Biotherapeutics Acquires Faeth Therapeutics and Raises US$200 Million in Private Placement - Global Legal Chronicle
SNSESensei Biotherapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Sensei Biotherapeutics Merges with Faeth Therapeutics, Secures $200M Funding - National Today
What is Sensei Biotherapeutics Inc. s revenue forecastJuly 2025 Trade Ideas & Precise Buy Zone Tips - mfd.ru
Sensei Biotherapeutics Acquires Faeth Therapeutics - Global Legal Chronicle
Sensei Biotherapeutics (SNSE) COO and director added as SEC insider - Stock Titan
Sensei Biotherapeutics Closes Faeth Acquisition and Financing - The Globe and Mail
Sensei Biotherapeutics Secures Future with Faeth Therapeutics Acquisition and $200M Financing - Beijing Times
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition - MSN
Sensei Biotherapeutics (SNSE) COO receives merger-linked equity awards - Stock Titan
Sensei Biotherapeutics Acquires Faeth Therapeutics and Secures $200 Million Funding - El-Balad.com
Sensei Biotherapeutics PIPE in Connection with its Acquisition of Faeth Therapeutics - Leerink Partners
Sensei/Faeth Merger Will Keep Both Firms’ Cancer Pipelines Active - Citeline News & Insights
Merger deal renews Faeth in Sensei; Piktor brightens, stock jumps - BioWorld MedTech
Small Cap Stocks To Add to Your WatchlistFebruary 18th - MarketBeat
Sensei Biotherapeutics Stock Soars 230% After Faeth Deal - Bitget
Why Is Sensei Biotherapeutics Stock Skyrocketing Wednesday?Sensei Biotherapeutics (NASDAQ:SNSE) - Benzinga
Sensei Biotherapeutics (SNSE) Shares Soar After $200M Acquisitio - GuruFocus
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Solve PI3K Resistance - HIT Consultant
Sensei steps back from brink by finding Faeth and its phase 2-stage cancer drug - Fierce Biotech
Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Advance Multi-Node Cancer Therapy for Endometrial and Breast Cancer - Femtech Insider
Sensei Jumps 150% On Faeth Therapeutics Buyout And $200M Financing - Nasdaq
Sensei Biotherapeutics stock soars after Faeth Therapeutics acquisition By Investing.com - Investing.com Canada
Sensei Biotherapeutics stock soars after Faeth Therapeutics acquisition - Investing.com
SNSE: Acquisition and $200M financing position the combined entity as a leader in multi-node cancer therapies - TradingView
Sensei Biotherapeutics Inc Stock (SNSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):